GeneDx Holdings Corp. in brief
GeneDx Holdings Corp. is a listed company, based in Stamford, Connecticut, USA. Its market value was $2.1 B on 30 October 2026, which makes it the 6,116th largest listed company in the world and the 1,592nd largest in the USA on this site. In the year to December 2025 it had sales of $428 M and a net loss of $21 M. Katherine Stueland is its chief executive. Its largest product and service lines by sales in 2025 were Diagnostic Test (97%), Patients with third-party insurance (81%) and Institutional customers (16%). Its shares trade under the symbol WGS (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About GeneDx Holdings Corp.
At GeneDx, our mission is to empower everyone to live their healthiest life through genomics. GeneDx combines clinical expertise, advanced technology, and the proprietary GeneDx Infinity™ dataset to power the ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device Designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx InfinityTM also fuels discovery for biopharma while supporting the network that we believe will drive the future of precision genetic medicine. We believe that what is best for patients must be embedded in every aspect of our work, and in support of these beliefs, we value equitability, simplicity, and transparency.
From the company's annual report filed with the US SEC: read the report
GeneDx Holdings Corp. timeline
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering as CM Life Sciences, Inc.Final prospectus filed with the SEC on 3 September 2020; shares registered for exchange trading on 31 August 2020.
- 2021
- ✎Renamed Sema4 Holdings Corp.Formerly CM Life Sciences, Inc..
- 2023
- ✎Renamed GeneDx Holdings Corp.Formerly Sema4 Holdings Corp..
- 2025
- 💰Record revenue of $428 millionFY2025, the highest of the 7 years on record.
Events of GeneDx Holdings Corp. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,555 (Oct 2026) · #1,593 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 4.6×
- Price / book
- 6.9×
- Free cash flow yield
- 0.7%
- Net margin (TTM)
- -24.1%
- Operating margin
- -3.1%
- Return on equity
- -36.0%
- Liabilities / assets
- 41.2%
- Net debt
- $-50M
- Revenue growth
- +40.0%
- R&D / revenue
- 16.8%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $428M | +40.0% | $-13M | $-21M | -4.9% |
| Dec 2024 | $305M | +50.8% | $-23M | $-52M | -17.1% |
| Dec 2023 | $203M | -13.7% | $-181M | $-176M | -86.8% |
| Dec 2022 | $235M | +10.6% | $-668M | $-549M | -233.9% |
| Dec 2021 | $212M | +18.3% | $-446M | $-245M | -115.6% |
| Dec 2020 | $179M | -8.6% | $-242M | $-241M | -134.6% |
| Dec 2019 | $196M | — | $-30M | $-30M | -15.1% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $33M | $19M | $14M | $-0.73 | — |
| Dec 2024 | $-29M | $5M | $-34M | $-1.94 | — |
| Dec 2023 | $-180M | $5M | $-185M | $-7.23 | — |
| Dec 2022 | $-319M | $7M | $-326M | $-53.63 | — |
| Dec 2021 | $-190M | $9M | $-200M | $-2.27 | — |
| Dec 2020 | $-93M | $24M | $-117M | $-47036.00 | — |
| Dec 2019 | $-19M | $12M | $-31M | — | — |
Quarterly results
Latest quarter to Sep 2026: revenue $123M (+5.4% on a year earlier), net income $-12M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Aug 3, 202610-QQuarterly report · period to Jun 2026
- Aug 3, 20268-KCurrent reportResults of operations
- Jun 23, 20268-KCurrent reportShareholder vote
- Jun 16, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- May 4, 202610-QQuarterly report · period to Mar 2026
- May 4, 20268-KCurrent reportResults of operations
- Apr 30, 2026DEF 14AProxy statement
- Mar 2, 20268-KCurrent reportMaterial agreement · Agreement ended · New financial obligation
- Feb 23, 202610-KAnnual report · period to Dec 2025
- Feb 23, 20268-KCurrent reportResults of operations
Official filings of GeneDx Holdings Corp. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $428 M
- Operating income
- $-13 M
- Net income
- $-21 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $524 M
- Total liabilities
- $216 M
- Total equity
- $308 M
As of December-2025
Top 100 institutional investors in GeneDx Holdings Corp.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Corvex Management LP | 4,784,570 | 0 (0.00%) | 15.96% | $346 M | Nov 16, 2026 |
| 2 | Casdin Capital, LLC | 3,707,164 | 0 (0.00%) | 12.37% | $268 M | Nov 16, 2026 |
| 3 | Goldman Sachs Group Inc | 2,102,780 | +433,339 (+25.96%) | 7.02% | $152 M | Nov 16, 2026 |
| 4 | ARK Investment Management LLC | 1,913,123 | +302,934 (+18.81%) | 6.38% | $138 M | Nov 13, 2026 |
| 5 | BlackRock, Inc. | 1,693,931 | -12,308 (-0.72%) | 5.65% | $122 M | Nov 13, 2026 |
| 6 | William Blair Investment Management, LLC | 1,560,247 | +159,594 (+11.39%) | 5.21% | $113 M | Nov 6, 2026 |
| 7 | Deep Track Capital, LP | 1,200,000 | +500,000 (+71.43%) | 4.00% | $87 M | Nov 16, 2026 |
| 8 | Millennium Management LLC | 1,089,123 | +933,548 (+600.06%) | 3.63% | $79 M | Nov 16, 2026 |
| 9 | Wellington Management Group LLP | 1,087,679 | +739,752 (+212.62%) | 3.63% | $79 M | Nov 16, 2026 |
| 10 | Morgan Stanley | 1,014,935 | +26,638 (+2.70%) | 3.39% | $73 M | Nov 13, 2026 |
| 11 | Vanguard Capital Management LLC | 948,762 | +69,759 (+7.94%) | 3.17% | $69 M | Nov 13, 2026 |
| 12 | First Light Asset Management, LLC | 786,901 | +2,978 (+0.38%) | 2.63% | $57 M | Nov 16, 2026 |
| 13 | D. E. Shaw & Co., Inc. | 673,610 | +634,733 (+1632.67%) | 2.25% | $49 M | Nov 16, 2026 |
| 14 | Citadel Advisors LLC | 668,709 | -196,753 (-22.73%) | 2.23% | $48 M | Nov 16, 2026 |
| 15 | Sumitomo Mitsui Trust Group, Inc. | 661,809 | -4,772 (-0.72%) | 2.21% | $48 M | Oct 29, 2026 |
| 16 | Amova Asset Management Americas, Inc. | 661,809 | -4,772 (-0.72%) | 2.21% | $48 M | Nov 13, 2026 |
| 17 | Assenagon Asset Management S.A. | 632,413 | +25,547 (+4.21%) | 2.11% | $46 M | Oct 15, 2026 |
| 18 | Geode Capital Management, LLC | 559,878 | +7,753 (+1.40%) | 1.87% | $40 M | Nov 6, 2026 |
| 19 | State Street Corp | 530,215 | +2,400 (+0.45%) | 1.77% | $38 M | Nov 12, 2026 |
| 20 | Gagnon Securities LLC | 516,284 | -8,581 (-1.63%) | 1.72% | $37 M | Nov 5, 2026 |
| 21 | Zweig-DiMenna Associates LLC | 358,100 | -213,850 (-37.39%) | 1.19% | $26 M | Nov 6, 2026 |
| 22 | Science & Technology Partners, L.P. | 335,435 | +229,048 (+215.30%) | 1.12% | $24 M | Nov 16, 2026 |
| 23 | Aberdeen Group plc | 322,405 | -134,796 (-29.48%) | 1.08% | $23 M | Nov 10, 2026 |
| 24 | Bank Of America Corp /de/ | 307,809 | -38,402 (-11.09%) | 1.03% | $22 M | Nov 16, 2026 |
| 25 | Dimensional Fund Advisors LP | 287,165 | +6,546 (+2.33%) | 0.96% | $21 M | Nov 4, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Eventide Asset Management, LLC | 269,485 | -57 (-0.02%) | 0.90% | $19 M | Nov 13, 2026 |
| 27 | Thrivent Financial for Lutherans | 227,628 | +125,636 (+123.18%) | 0.76% | $16 M | Nov 5, 2026 |
| 28 | Portolan Capital Management, LLC | 199,770 | -545 (-0.27%) | 0.67% | $14 M | Nov 16, 2026 |
| 29 | Charles Schwab Investment Management Inc | 197,770 | +19,833 (+11.15%) | 0.66% | $14 M | Nov 16, 2026 |
| 30 | Vanguard Portfolio Management LLC | 194,169 | -3,409 (-1.73%) | 0.65% | $14 M | Nov 13, 2026 |
| 31 | Northern Trust Corp | 184,016 | +175 (+0.10%) | 0.61% | $13 M | Nov 16, 2026 |
| 32 | Franklin Templeton Inc | 183,061 | -97,877 (-34.84%) | 0.61% | $13 M | Nov 12, 2026 |
| 33 | Jpmorgan Chase & Co | 168,587 | +114,200 (+209.98%) | 0.56% | $12 M | Nov 12, 2026 |
| 34 | Alamea Verwaltungs GmbH | 167,041 | -18,948 (-10.19%) | 0.56% | $12 M | Nov 16, 2026 |
| 35 | Gagnon Advisors, LLC | 163,024 | -14,846 (-8.35%) | 0.54% | $12 M | Nov 6, 2026 |
| 36 | Vanguard Fiduciary Trust Co | 159,745 | +6,880 (+4.50%) | 0.53% | $12 M | Nov 13, 2026 |
| 37 | LMR Partners LLP | 146,822 | New | 0.49% | $11 M | Nov 16, 2026 |
| 38 | Fred Alger Management, LLC | 135,828 | +27,301 (+25.16%) | 0.45% | $10 M | Nov 16, 2026 |
| 39 | Ashford Capital Management Inc | 125,684 | -76,302 (-37.78%) | 0.42% | $9 M | Nov 16, 2026 |
| 40 | FMR LLC | 121,242 | +114,110 (+1599.97%) | 0.40% | $9 M | Nov 10, 2026 |
| 41 | BNP Paribas Financial Markets | 118,901 | -4,789 (-3.87%) | 0.40% | $9 M | Nov 12, 2026 |
| 42 | Legal Advantage Investments, Inc. | 98,845 | +31,800 (+47.43%) | 0.33% | $7 M | Oct 13, 2026 |
| 43 | UBS Group AG | 97,926 | -110,737 (-53.07%) | 0.33% | $7 M | Nov 10, 2026 |
| 44 | Rockefeller Capital Management L.P. | 97,743 | -53,421 (-35.34%) | 0.33% | $7 M | Nov 13, 2026 |
| 45 | Tudor Investment Corp Et Al | 85,829 | -23,010 (-21.14%) | 0.29% | $6 M | Nov 16, 2026 |
| 46 | IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 79,971 | +13,755 (+20.77%) | 0.27% | $6 M | Nov 13, 2026 |
| 47 | Blackstone Inc. | 79,918 | New | 0.27% | $6 M | Nov 16, 2026 |
| 48 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 77,229 | -76 (-0.10%) | 0.26% | $6 M | Nov 13, 2026 |
| 49 | Trexquant Investment LP | 64,804 | New | 0.22% | $5 M | Nov 16, 2026 |
| 50 | EFG International AG | 62,001 | +17,049 (+37.93%) | 0.21% | $4 M | Nov 16, 2026 |
| 51 | Bank of New York Mellon Corp | 60,862 | -1,166 (-1.88%) | 0.20% | $4 M | Nov 5, 2026 |
| 52 | Jump Financial, LLC | 57,174 | New | 0.19% | $4 M | Nov 13, 2026 |
| 53 | Quantinno Capital Management LP | 54,849 | +1,395 (+2.61%) | 0.18% | $4 M | Nov 13, 2026 |
| 54 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 54,627 | +17,688 (+47.88%) | 0.18% | $4 M | Nov 16, 2026 |
| 55 | Nuveen, LLC | 53,818 | +7,660 (+16.60%) | 0.18% | $4 M | Nov 10, 2026 |
| 56 | Nia Impact Advisors, LLC | 47,238 | +507 (+1.08%) | 0.16% | $3 M | Nov 4, 2026 |
| 57 | Corient Private Wealth LP | 44,293 | -365 (-0.82%) | 0.15% | $3 M | Nov 16, 2026 |
| 58 | Russell Investments Group, Ltd. | 44,167 | +32,286 (+271.74%) | 0.15% | $3 M | Nov 6, 2026 |
| 59 | Kovack Advisors, Inc. | 42,917 | -175 (-0.41%) | 0.14% | $3 M | Nov 13, 2026 |
| 60 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 39,662 | -14,674 (-27.01%) | 0.13% | $3 M | Nov 16, 2026 |
| 61 | Royce & Associates LP | 39,640 | -72,496 (-64.65%) | 0.13% | $3 M | Nov 9, 2026 |
| 62 | Envestnet Asset Management Inc | 39,390 | -3,651 (-8.48%) | 0.13% | $3 M | Nov 16, 2026 |
| 63 | AQR Capital Management LLC | 39,308 | +10,136 (+34.75%) | 0.13% | $3 M | Nov 16, 2026 |
| 64 | Lazard Asset Management LLC | 38,844 | +5,992 (+18.24%) | 0.13% | $3 M | Nov 16, 2026 |
| 65 | RBF Capital, LLC | 37,340 | 0 (0.00%) | 0.12% | $3 M | Nov 13, 2026 |
| 66 | Moody Aldrich Partners LLC | 36,064 | +20,511 (+131.88%) | 0.12% | $3 M | Oct 27, 2026 |
| 67 | Swiss National Bank | 36,000 | -4,000 (-10.00%) | 0.12% | $3 M | Nov 12, 2026 |
| 68 | Connor, Clark & Lunn Investment Management Ltd. | 35,141 | New | 0.12% | $3 M | Nov 10, 2026 |
| 69 | Slow Capital, Inc. | 34,527 | -7,973 (-18.76%) | 0.12% | $2 M | Oct 23, 2026 |
| 70 | Citigroup Inc | 33,840 | -20,054 (-37.21%) | 0.11% | $2 M | Nov 4, 2026 |
| 71 | XTX Topco Ltd | 33,709 | New | 0.11% | $2 M | Nov 16, 2026 |
| 72 | Susquehanna International Group, LLP | 30,799 | -111,516 (-78.36%) | 0.10% | $2 M | Nov 16, 2026 |
| 73 | First Trust Advisors LP | 30,312 | New | 0.10% | $2 M | Nov 12, 2026 |
| 74 | Vestmark Advisory Solutions, Inc. | 30,098 | -1,993 (-6.21%) | 0.10% | $2 M | Nov 16, 2026 |
| 75 | Stempoint Capital LP | 29,275 | New | 0.10% | $2 M | Nov 16, 2026 |
| 76 | Price T Rowe Associates Inc /MD/ | 28,988 | +97 (+0.34%) | 0.10% | $2 M | Nov 16, 2026 |
| 77 | SRS Investment Management, LLC | 25,752 | New | 0.09% | $2 M | Nov 16, 2026 |
| 78 | Rhumbline Advisers | 25,222 | +39 (+0.15%) | 0.08% | $2 M | Nov 10, 2026 |
| 79 | Virtu Financial LLC | 24,156 | New | 0.08% | $2 M | Nov 17, 2026 |
| 80 | Wells Fargo & Company/mn | 23,461 | -5,677 (-19.48%) | 0.08% | $2 M | Nov 16, 2026 |
| 81 | California State Teachers Retirement System | 21,935 | 0 (0.00%) | 0.07% | $2 M | Nov 13, 2026 |
| 82 | Deutsche Bank AG\ | 20,293 | -1,587 (-7.25%) | 0.07% | $1 M | Nov 6, 2026 |
| 83 | Invesco Ltd. | 20,215 | +219 (+1.10%) | 0.07% | $1 M | Nov 12, 2026 |
| 84 | Alliancebernstein L.P. | 20,050 | 0 (0.00%) | 0.07% | $1 M | Nov 16, 2026 |
| 85 | Squarepoint Ops LLC | 18,621 | New | 0.06% | $1 M | Nov 9, 2026 |
| 86 | WINTON GROUP Ltd | 18,504 | New | 0.06% | $1 M | Nov 12, 2026 |
| 87 | IMC-Chicago, LLC | 17,927 | +5,133 (+40.12%) | 0.06% | $1 M | Nov 5, 2026 |
| 88 | Fox Run Management, L.L.C. | 17,526 | +10,260 (+141.21%) | 0.06% | $1 M | Nov 12, 2026 |
| 89 | Legal & General Group Plc | 17,354 | -438 (-2.46%) | 0.06% | $1 M | Nov 16, 2026 |
| 90 | FORA Capital, LLC | 16,393 | -16,832 (-50.66%) | 0.05% | $1 M | Nov 13, 2026 |
| 91 | ExodusPoint Capital Management, LP | 16,252 | -8,922 (-35.44%) | 0.05% | $1 M | Nov 16, 2026 |
| 92 | Quadrature Capital Ltd | 15,209 | -5,213 (-25.53%) | 0.05% | $1 M | Nov 13, 2026 |
| 93 | Walleye Capital LLC | 15,005 | -52,895 (-77.90%) | 0.05% | $1 M | Nov 13, 2026 |
| 94 | Meridiem Capital Partners LP | 14,099 | -32,665 (-69.85%) | 0.05% | $1 M | Nov 16, 2026 |
| 95 | Dark Forest Capital Management LP | 14,051 | +570 (+4.23%) | 0.05% | $1 M | Nov 16, 2026 |
| 96 | Manufacturers Life Insurance Company, The | 13,306 | +1,518 (+12.88%) | 0.04% | $1 M | Nov 13, 2026 |
| 97 | VANGUARD ASSET MANAGEMENT, Ltd | 13,214 | -80 (-0.60%) | 0.04% | $1 M | Nov 13, 2026 |
| 98 | Algert Global LLC | 12,932 | -9,000 (-41.04%) | 0.04% | $1 M | Nov 17, 2026 |
| 99 | Osaic Holdings, Inc. | 12,255 | +4,927 (+67.24%) | 0.04% | $1 M | Nov 12, 2026 |
| 100 | MetLife Investment Management, LLC | 11,538 | 0 (0.00%) | 0.04% | $1 M | Nov 16, 2026 |
Mutual funds holding GeneDx Holdings Corp.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 ARK Innovation ETFARK Investment Management LLC | 876,607 | $57 M | 2.9% | 1.0% | +5.5% | Jul 31, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 607,773 | $42 M | 2.0% | <0.01% | +1.4% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 523,338 | $36 M | 1.7% | 0.04% | +12% | Jun 30, 2026 |
| 🇺🇸 ARK Genomic Revolution ETFARK Investment Management LLC | 446,965 | $29 M | 1.5% | 1.9% | +11% | Jul 31, 2026 |
| 🇺🇸 Eventide Gilead FundEventide Asset Management, LLC | 266,042 | $18 M | 0.89% | 0.53% | +56% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 249,890 | $17 M | 0.83% | 0.02% | +4.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 218,876 | $14 M | 0.73% | 0.04% | +16% | Jul 31, 2026 |
| 🇺🇸 Franklin Small Cap Growth FundFranklin Advisers, Inc. | 201,666 | $13 M | 0.67% | 0.53% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 184,614 | $13 M | 0.62% | 0.08% | +19% | Jun 30, 2026 |
| 🇺🇸 abrdn Healthcare Opportunities Fundabrdn Inc. | 171,640 | $12 M | 0.57% | 1.4% | +85% | Jun 30, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 222,516 | $12 M | 0.74% | 0.01% | +123% | May 31, 2026 |
| 🇺🇸 abrdn Healthcare Investorsabrdn Inc. | 163,598 | $11 M | 0.55% | 0.82% | +122% | Jun 30, 2026 |
| 🇺🇸 William Blair Small-Mid Cap Growth FundWilliam Blair Investment Management, LLC | 126,588 | $9 M | 0.42% | 0.66% | +73% | Jun 30, 2026 |
| 🇺🇸 William Blair Small Cap Growth FundWilliam Blair Investment Management, LLC | 125,324 | $9 M | 0.42% | 0.70% | +103% | Jun 30, 2026 |
| 🇺🇸 Alger Small Cap Focus FundFred Alger Management, LLC | 130,474 | $8 M | 0.44% | 1.00% | +8.2% | Jul 31, 2026 |
| 🇺🇸 Thrivent Small-Mid Cap Equity ETFThrivent Asset Management LLC | 101,992 | $7 M | 0.34% | 0.67% | +13% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 97,509 | $6 M | 0.33% | 0.04% | +24% | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 110,973 | $6 M | 0.37% | 0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 103,149 | $5 M | 0.34% | 0.02% | −1.0% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 97,760 | $5 M | 0.33% | 0.03% | +3.8% | May 31, 2026 |
| 🇺🇸 ARK Venture FundARK Investment Management LLC | 76,976 | $5 M | 0.26% | 0.42% | +25% | Jul 31, 2026 |
| 🇺🇸 abrdn World Healthcare Fundabrdn Inc. | 71,515 | $5 M | 0.24% | 0.87% | +98% | Jun 30, 2026 |
| 🇺🇸 Royce Micro-Cap Trust, Inc.Royce & Associates, LP | 70,970 | $5 M | 0.24% | 0.54% | +125% | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 71,590 | $5 M | 0.24% | 0.06% | +4.1% | Jul 31, 2026 |
| 🇺🇸 abrdn Life Sciences Investorsabrdn Inc. | 67,565 | $5 M | 0.23% | 0.67% | +145% | Jun 30, 2026 |
| 🇺🇸 Principal U.S. Small-Cap ETFPrincipal Global Investors, LLC | 66,880 | $5 M | 0.22% | 0.20% | +7.6% | Jun 30, 2026 |
| 🇺🇸 Calamos Timpani Small Cap Growth FundCalamos Advisors LLC | 56,759 | $4 M | 0.19% | 0.48% | +127% | Jul 31, 2026 |
| 🇺🇸 Timothy Plan Small/Mid Cap Growth FundTimothy Partners, Ltd. | 53,556 | $4 M | 0.18% | 2.1% | +94% | Jun 30, 2026 |
| 🇺🇸 The Hartford Small Company FundHartford Funds Management Company, LLC | 56,384 | $4 M | 0.19% | 0.54% | −1.6% | Jul 31, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 60,640 | $3 M | 0.20% | 0.02% | +0.2% | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 48,408 | $3 M | 0.16% | 0.04% | +16% | Jul 31, 2026 |
| 🇺🇸 Small Cap Growth Stock PortfolioMason Street Advisors, LLC | 42,072 | $3 M | 0.14% | 0.32% | +9.1% | Jun 30, 2026 |
| 🇺🇸 State Street SPDR S&P Health Care Services ETFSSGA Funds Management, Inc. | 41,617 | $3 M | 0.14% | 2.0% | — | Jun 30, 2026 |
| 🇺🇸 iShares U.S. Healthcare Providers ETFBlackRock Fund Advisors | 39,630 | $3 M | 0.13% | 0.23% | +58% | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 37,388 | $3 M | 0.12% | 0.04% | +19% | Jun 30, 2026 |
| 🇺🇸 Hartford Small Company HLS FundHartford Funds Management Company, LLC | 36,611 | $3 M | 0.12% | 0.53% | no change | Jun 30, 2026 |
| 🇺🇸 Royce Micro-Cap FundRoyce & Associates, LP | 31,054 | $2 M | 0.10% | 0.50% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 40,511 | $2 M | 0.14% | <0.01% | +2.1% | May 31, 2026 |
| 🇺🇸 Hartford Small Cap Growth HLS FundHartford Funds Management Company, LLC | 30,559 | $2 M | 0.10% | 0.31% | +15% | Jun 30, 2026 |
| 🇺🇸 Carillon Chartwell Small Cap FundCarillon Tower Advisers, Inc. | 28,326 | $2 M | 0.09% | 0.77% | +13% | Jun 30, 2026 |
| 🇺🇸 Franklin Small Cap Enhanced ETFFranklin Advisers, Inc. | 28,069 | $2 M | 0.09% | 1.5% | +139% | Jun 30, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 27,725 | $2 M | 0.09% | <0.01% | +2.0% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 26,473 | $2 M | 0.09% | 0.04% | +19% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 32,524 | $2 M | 0.11% | <0.01% | +2.7% | May 31, 2026 |
| 🇺🇸 William Blair Small-Mid Cap Core FundWilliam Blair Investment Management, LLC | 24,537 | $2 M | 0.08% | 0.63% | +172% | Jun 30, 2026 |
| 🇺🇸 First Trust Small Cap Growth AlphaDEX FundFirst Trust Advisors L.P. | 25,089 | $2 M | 0.08% | 0.13% | new | Jul 31, 2026 |
| 🇺🇸 Alger Small Cap Growth PortfolioFred Alger Management, LLC | 23,544 | $2 M | 0.08% | 0.98% | −34% | Jun 30, 2026 |
| 🇺🇸 Small Cap Stock TrustJohn Hancock Variable Trust Advisers LLC | 23,101 | $2 M | 0.08% | 0.53% | −1.8% | Jun 30, 2026 |
| 🇺🇸 American Beacon ARK Transformational Innovation FundAmerican Beacon Advisors, Inc. | 22,234 | $2 M | 0.07% | 0.95% | +4.2% | Jun 30, 2026 |
| 🇺🇸 Carillon Chartwell Small Cap Growth FundCarillon Tower Advisers, Inc. | 21,929 | $2 M | 0.07% | 0.77% | +32% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 21,794 | $1 M | 0.07% | 0.04% | +9.7% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 18,741 | $1 M | 0.06% | 0.08% | +30% | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 18,197 | $1 M | 0.06% | <0.01% | +164% | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 17,892 | $1 M | 0.06% | <0.01% | −76% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 17,852 | $1 M | 0.06% | <0.01% | +46% | Jul 31, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC | 22,200 | $1 M | 0.07% | 0.02% | −22% | May 29, 2026 |
| 🇺🇸 MassMutual Small Cap Growth Equity FundMML Investment Advisers, LLC | 15,963 | $1 M | 0.05% | 0.15% | −45% | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 16,421 | $1 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 William Blair Growth FundWilliam Blair Investment Management, LLC | 15,156 | $1 M | 0.05% | 0.46% | +18% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 14,200 | $1 M | 0.05% | 0.04% | +11% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 17,779 | $1 M | 0.06% | 0.05% | +1.9% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 17,559 | $1 M | 0.06% | <0.01% | +4.9% | May 31, 2026 |
| 🇺🇸 Alger Small Cap Growth FundFred Alger Management, LLC | 13,974 | $1 M | 0.05% | 0.45% | −42% | Jul 31, 2026 |
| 🇺🇸 The Hartford Small Cap Growth FundHartford Funds Management Company, LLC | 13,750 | $1 M | 0.05% | 0.32% | −10% | Jul 31, 2026 |
| 🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors | 13,700 | $1 M | 0.05% | 0.02% | +133% | Jul 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 13,176 | $1 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 NYLIM VP Wellington Small Cap PortfolioNew York Life Investment Management LLC | 12,177 | $1 M | 0.04% | 0.19% | −8.8% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 12,035 | $1 M | 0.04% | <0.01% | +9.6% | Jul 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 10,450 | $1 M | 0.03% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 10,312 | $1 M | 0.03% | <0.01% | −3.9% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 10,124 | $1 M | 0.03% | 0.04% | +17% | Jun 30, 2026 |
| 🇺🇸 Royce Capital Fund - Micro-Cap PortfolioRoyce & Associates, LP | 10,112 | $1 M | 0.03% | 0.49% | — | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 12,363 | $1 M | 0.04% | 0.07% | +1.3% | May 31, 2026 |
| 🇺🇸 iShares ESG Aware MSCI USA Small-Cap ETFBlackRock Fund Advisors | 12,330 | $1 M | 0.04% | 0.03% | +56% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 12,226 | $1 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 LVIP Franklin Templeton Multi-Factor SMID Cap Equity FundLincoln Financial Investments Corporation | 9,089 | $1 M | 0.03% | 0.06% | +6.7% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 9,574 | $1 M | 0.03% | 0.04% | +16% | Jul 31, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds | 9,045 | $1 M | 0.03% | 0.07% | +27% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 8,978 | $1 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC | 9,458 | $1 M | 0.03% | 0.02% | +2.9% | Jul 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 8,774 | $1 M | 0.03% | 0.02% | +24% | Jul 31, 2026 |
| 🇺🇸 One Global ETFThe Future Fund LLC | 10,837 | $1 M | 0.04% | 0.55% | — | May 31, 2026 |
| 🇺🇸 iShares Morningstar Small-Cap Growth ETFBlackRock Fund Advisors | 8,113 | $1 M | 0.03% | 0.05% | +28% | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 8,092 | $1 M | 0.03% | 0.02% | +7.9% | Jul 31, 2026 |
| 🇺🇸 Thrivent Aggressive Allocation FundThrivent Asset Management LLC | 7,917 | $1 M | 0.03% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Multi-Manager U.S. Small Cap Equity FundGoldman Sachs Asset Management, L.P. | 7,818 | $0 M | 0.03% | 0.14% | — | Apr 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 6,860 | $0 M | 0.02% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 6,800 | $0 M | 0.02% | 0.02% | +1.5% | Jun 30, 2026 |
| 🇺🇸 Thrivent Moderately Aggressive Allocation FundThrivent Asset Management LLC | 7,158 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 JPMorgan BetaBuilders U.S. Small Cap Equity ETFJ.P. Morgan Investment Management Inc. | 6,851 | $0 M | 0.02% | 0.06% | −11% | Jul 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 6,434 | $0 M | 0.02% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC | 6,719 | $0 M | 0.02% | 0.17% | +64% | Jul 31, 2026 |
| 🇺🇸 MML VIP Wellington Small Cap Growth Equity FundMML Investment Advisers, LLC | 6,241 | $0 M | 0.02% | 0.27% | −1.0% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 6,196 | $0 M | 0.02% | 0.04% | +6.5% | Jun 30, 2026 |
| 🇸🇪 Handelsbanken Global Småbolag Index CriteriaHandelsbanken Fonder AB | 6,200 | $0 M | 0.02% | 0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 7,767 | $0 M | 0.03% | 0.03% | no change | May 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 5,777 | $0 M | 0.02% | 0.04% | +19% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC | 7,227 | $0 M | 0.02% | <0.01% | +1.7% | May 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 5,173 | $0 M | 0.02% | 0.04% | +5.6% | Jun 30, 2026 |
| 🇺🇸 MFS Blended Research Small Cap Equity FundMASSACHUSETTS FINANCIAL SERVICES COMPANY | 6,127 | $0 M | 0.02% | 0.10% | −75% | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at GeneDx Holdings Corp.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Thomas FuchsDirector | Option exercise | +1,146 | — | — | 1,146 | Form 4 |
| filed | Katherine StuelandCHIEF EXECUTIVE OFFICER, Director | Option exercise | +18,750 | — | — | 125,977 | Form 4 |
| filed | Kevin FeeleyCHIEF FINANCIAL OFFICER | Option exercise | +7,197 | — | — | 48,673 | Form 4 |
| filed | Kevin FeeleyCHIEF FINANCIAL OFFICER | Sell | -586 | $94.26 | $55 K | 48,087 | Form 4 |
| filed | Katherine StuelandCHIEF EXECUTIVE OFFICER, Director | Sell | -1,648 | $94.26 | $155 K | 124,329 | Form 4 |
| filed | Kevin FeeleyCHIEF FINANCIAL OFFICER | Sell | -52 | $95.41 | $5 K | 48,035 | Form 4 |
| filed | Katherine StuelandCHIEF EXECUTIVE OFFICER, Director | Sell | -148 | $95.41 | $14 K | 124,181 | Form 4 |
| filed | Katherine StuelandCHIEF EXECUTIVE OFFICER, Director | Sell | -1,525 | $96.90 | $148 K | 122,656 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: GeneDx Holdings Corp.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-33.33 reverse split
Fails to deliver
- : 459 shares at $71.02
- : 1,833 shares at $64.69
- : 120 shares at $61.26
- : 7,286 shares at $66.29
- : 8 shares at $76.27
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
GeneDx Holdings Corp. scorecard#
Passes 9 of the 18 checks that could be worked out: strongest in growth (4 of 5), weakest in valuation (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 3
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- –Price to book below its peers' medianToo few peers with a current market cap for a median.
- –Price to sales below its peers' medianToo few peers with a current market cap for a median.
- ✗Free cash flow yield above 5%0.7%Free cash flow is 0.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 5
- ✓Revenue grew in the newest year40.0%Revenue up 40.0% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years22.1%22.1% a year over the three years to fiscal 2025.
- –Faster growth over three years than its peers' medianToo few peers for a median.
- ✗Earnings per share grew in the newest year-0.73 vs -1.94Diluted EPS -0.73 in fiscal 2025 against -1.94 the year before (report's currency).
- ✓Net income higher than five years earlier-$21 M-$21 M in fiscal 2025 against -$241 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability1 of 4
- ✗Profitable in the newest year-$21 MNet income -$21 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianToo few peers for a median.
- ✗Return on equity above 15%-7.6%-7.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-3.1%-3.1% in fiscal 2025 against -284.5% in 2022.
Financial health4 of 5
- ✓Short-term assets cover short-term liabilities2.5×Current ratio 2.46 at the end of fiscal 2025.
- ✓Debt below equity0.2×Debt to equity 0.18 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $50 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone3.35Z-score 3.35 (safe zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year6.5%Diluted shares up 6.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from GeneDx Holdings Corp.'s statements.
| Ratio | Trend | 2025 |
|---|---|---|
| Operating margin | -3.1% | |
| Net margin | -4.9% | |
| Return on equity | -7.6% | |
| Revenue growth, 3 years a year | 22.1% | |
| Revenue growth | 40.0% | |
| Debt to equity | 0.18× |
6of 9on the Piotroski tests of financial strength
- Net loss of $21 million, the 7th loss-making year in a row.
- The share count rose 6.5% in the year.
- Receivables grew 98% while revenue grew 40%: customers are paying later, or sales were booked ahead of cash.
- More cash than debt: net cash of $50 million.
GeneDx Holdings Corp.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 428+40.0%100% | 305+50.8%100% | 203−13.7%100% | 235+10.6%100% | 212+18.3%100% | 179−8.6%100% | 196—100% | |
| Cost of revenue | 129+16.5%30.3% | 111−1.3%36.4% | 113−56.9%55.6% | 261+14.3%111% | 229+30.5%108% | 175+54.6%97.8% | 113—57.8% | |
| Gross profit | 298+53.4%69.7% | 194+116%63.6% | 90—44.4% | −27—−11.4% | −17−512%−7.8% | 4.0−95.1%2.2% | 83—42.2% | |
| Research and development | 72+57.5%16.8% | 46−21.5%15.0% | 58−32.4%28.8% | 86−18.0%36.7% | 105+44.7%49.6% | 73+108%40.5% | 35—17.8% | |
| Selling and marketing | 88+31.2%20.7% | 67+10.5%22.1% | 61−50.1%30.1% | 122r135+8.3%52.0% | 113+78.4%53.1% | 63+60.6%35.2% | 39—20.1% | |
| General and administrative | 151+44.3%35.3% | 105r101−24.8%34.2% | 139r134−35.7%68.6% | 216r203+4.9%92.1% | 206+104%97.1% | 101+242%56.2% | 29—15.0% | |
| Operating income | −13—−3.1% | −23—−7.6% | −181—−89.2% | −668—−284% | −446—−210% | −242—−135% | −30—−15.5% | |
| Interest and finance income | — | — | — | 2.5+3116%1.1% | 0.1−84.4%0.0% | 0.5−48.8%0.3% | 1.0—0.5% | |
| Interest expense and finance costs | — | — | — | 3.2+13.1%1.4% | 2.8+14.6%1.3% | 2.5+216%1.4% | 0.8—0.4% | |
| Net interest income | — | — | 1.1—0.5% | −0.7—−0.3% | — | — | — | |
| Other non-operating income (expense) | −8.1—−1.9% | −29−854%−9.6% | 3.9−94.4%1.9% | 70−65.3%29.7% | 201+30597%94.6% | 0.7−7.8%0.4% | 0.7—0.4% | |
| Income before tax | −21—−4.9% | −53—−17.2% | −177—−87.2% | −598—−255% | −245—−116% | −241—−135% | −30—−15.1% | |
| Income tax | −0.1—−0.0% | −0.3—−0.1% | −0.9—−0.5% | −49—−20.9% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Net income attributable to shareholders | −21—−4.9% | −52—−17.1% | −176—−86.8% | −549—−234% | −245—−116% | −241—−135% | −30—−15.1% | |
| Earnings per share, basic | -0.73—— | -1.94—— | -7.23—— | -53.63r-1.63—— | -2.27—— | -47,036.00—— | -264,056.00—— | |
| Earnings per share, diluted | -0.73—— | -1.94—— | -7.23—— | -53.63r-1.63—— | -2.27—— | -47,036.00—— | -264,056.00—— | |
| Shares, weighted average (basic) | 29+6.5%— | 27+10.6%— | 24+137%— | 10r338−90.5%— | 108+2106262%— | 0.0+4038%— | 0.0—— | |
| Shares, weighted average (diluted) | 29+6.5%— | 27+10.6%— | 24+137%— | 10r338−90.5%— | 108+2106262%— | 0.0+4038%— | 0.0—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 105+23.2%20.0% | 85−14.5%20.3% | 100−19.6%23.8% | 124−69.1%25.2% | 401+270%72.3% | 108r1.1−6.0%43.0% | 115—— | |
| Short-term investments | 66+18.4%12.7% | 56+83.7%13.3% | 30—7.3% | 0—0.0% | — | — | — | |
| Receivables | 74+97.6%14.2% | 38r37—9.0% | — | 43+60.8%8.7% | 27−17.3%4.8% | 32—12.7% | — | |
| Inventory | 14+31.0%2.7% | 11+21.3%2.5% | 8.8−35.8%2.1% | 14−59.2%2.8% | 33+34.0%6.0% | 25—9.9% | — | |
| Other current assets | 1.5+40.0%0.3% | 1.1r1.1−44.9%0.3% | 2.0r11−69.4%0.5% | 6.4+68.1%1.3% | 3.8−7.8%0.7% | 4.1—1.6% | — | |
| Current assets | 268+35.5%51.2% | 198+8.6%47.2% | 182−14.2%43.5% | 213−56.0%43.3% | 484+178%87.3% | 174r1.4—69.2% | — | |
| Property, plant and equipment | 46+38.9%8.7% | 33+1.3%7.8% | 32−37.0%7.8% | 52−17.8%10.5% | 63−0.6%11.3% | 63—25.1% | — | |
| Right-of-use (leased) assets | 23−8.6%4.5% | 26−4.8%6.1% | 27−17.9%6.4% | 33—6.7% | 0—0.0% | — | — | |
| Goodwill | 14—2.6% | 0—0.0% | — | — | 0—0.0% | 0—0.0% | — | |
| Other intangible assets | 168+6.2%32.2% | 159−8.1%37.8% | 173−7.5%41.2% | 187—38.0% | 0—0.0% | — | — | |
| Total assets | 524+24.9%100% | 419+0.1%100% | 419−14.7%100% | 491−11.4%100% | 554+120%100% | 252r444—100% | — | |
| Accounts payable | 2.5−69.1%0.5% | 8.0−22.3%1.9% | 10−77.8%2.4% | 46+3.0%9.4% | 45+67.2%8.1% | 27r0.1—10.6% | — | |
| Debt due within a year | 4.5+275%0.9% | 1.2+144%0.3% | 0.5−89.5%0.1% | 4.8—1.0% | 0−100%0.0% | 1.8—0.7% | — | |
| Current liabilities | 109+98.7%20.8% | 55−6.8%13.1% | 59−59.2%14.0% | 144+42.5%29.4% | 101+37.9%18.3% | 73r0.1—29.2% | — | |
| Long-term debt | 48−7.2%9.2% | 52−1.5%12.4% | 53+743%12.6% | 6.3−43.2%1.3% | 11−42.0%2.0% | 19—7.5% | — | |
| Lease liabilities (non-current) | 39−9.2%7.4% | 43−3.9%10.2% | 44−0.1%10.6% | 44—9.1% | — | — | — | |
| Total liabilities | 216+23.8%41.2% | 174−8.7%41.5% | 191−19.6%45.5% | 237+42.9%48.3% | 166−32.9%30.0% | 247r16—98.3% | — | |
| Retained earnings | −1,373—−262% | −1,352—−322% | −1,300—−310% | −1,124—−229% | −575—−104% | −330r−0.2—−131% | — | |
| Shareholders' equity | 308+25.7%58.8% | 245+7.6%58.5% | 228−10.1%54.5% | 254−34.6%51.7% | 388—70.0% | −330r5.0—−131% | −89—— | |
| Total liabilities and equity | 524+24.9%100% | 419+0.1%100% | 419−14.7%100% | 491−11.4%100% | 554+120%100% | 252r444—100% | — | |
| Shares outstanding | 29+4.4%— | 28+7.8%— | 26+121%— | 12−95.1%— | 243—— | — | — | |
| Cash-flow statement | ||||||||
| Depreciation and amortization | 9.6+21.5%2.2% | 7.9−59.9%2.6% | 20−60.6%9.7% | 50r59+129%21.3% | 22+85.8%10.3% | 12+83.1%6.5% | 6.4—3.3% | |
| Share-based compensation | 32+252%7.5% | 9.1—3.0% | −0.3−101%−0.2% | 42−80.9%17.9% | 219+82.5%103% | 120+2093%67.0% | 5.5—2.8% | |
| Cash from operating activities | 33—7.8% | −28—−9.3% | −180—−88.9% | −319—−136% | −190—−89.7% | −93—−51.9% | −19—−9.5% | |
| Capital expenditure | −19—−4.4% | −5.5—−1.8% | −5.3—−2.6% | −7.2—−3.0% | −9.4—−4.4% | −24—−13.4% | −12—−6.1% | |
| Acquisitions, net of cash acquired | — | 0—0.0% | −12—−6.0% | −127—−54.1% | 0—0.0% | 0—0.0% | — | |
| Cash from investing activities | −62—−14.4% | −30—−9.9% | −44—−21.6% | −141—−60.2% | −21—−9.8% | −32—−17.8% | −15—−7.9% | |
| Debt issued | 0—0.0% | 0−100%0.0% | 49—24.0% | 0—0.0% | 0−100%0.0% | 16—8.9% | 0—0.0% | |
| Shares issued | — | — | — | 198−43.5%84.2% | 350—165% | 0—0.0% | 0—0.0% | |
| Cash from financing activities | 48+8.7%11.2% | 44−76.3%14.5% | 186−5.6%91.9% | 197−60.0%84.1% | 494+283%233% | 129−12.8%72.0% | 148—75.4% | |
| Change in cash | 20—4.6% | −14—−4.7% | −38—−18.6% | −263−193%−112% | 283+7045%133% | 4.0−96.5%2.2% | 114—58.0% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 461+14.6%100% | 123+5.4%100% | 114+11.4%100% | 102+17.4%100% | 121*+26.5%100% | 117+51.9%100% | 103+45.6%100% | 87+39.6%100% | 96*+66.6%100% | 77—100% | 71—100% | 62—100% | 57*—100% | |
| Cost of revenue | 144+18.0%31.3% | 37+15.0%30.1% | 36+13.9%31.6% | 34+18.9%33.3% | 37*+24.8%30.4% | 32+10.9%27.6% | 32+15.3%31.0% | 29+14.5%32.9% | 29*+10.4%30.8% | 29—37.8% | 28—39.1% | 25—40.1% | 27*—46.4% | |
| Gross profit | 317+13.1%68.7% | 86+1.8%69.9% | 78+10.3%68.4% | 68+16.6%66.7% | 84*+27.3%69.6% | 85+76.7%72.4% | 71+65.1%69.0% | 58+56.3%67.1% | 66*+115%69.2% | 48—62.2% | 43—60.9% | 37—59.9% | 31*—53.6% | |
| Research and development | 81+37.7%17.7% | 17−12.4%14.1% | 20+30.4%17.2% | 20+57.5%19.4% | 25*+112%20.3% | 20+70.0%17.0% | 15+38.3%14.7% | 13+8.7%14.4% | 12*−5.4%12.1% | 12—15.2% | 11—15.5% | 12—18.5% | 12*—21.3% | |
| Selling, general and administrative | — | 79+16.4%64.3% | 76+62.3%66.4% | 75+47.9%72.9% | — | 68—58.2% | 47—45.6% | 50—57.9% | — | — | — | — | — | |
| Selling and marketing | — | — | — | — | 27*+53.5%22.4% | 24+38.1%20.1% | 19+17.3%18.9% | 18+13.9%21.0% | 18*+13.6%18.5% | 17—22.1% | 17—23.5% | 16—25.8% | 16*—27.1% | |
| General and administrative | — | — | — | — | 47*+66.5%38.7% | 44+65.1%38.1% | 27+5.3%26.7% | 32+37.2%36.9% | 28r27*−11.8%29.4% | 27r26—35.0% | 26r25—36.9% | 23r22—37.5% | 32r27*—55.5% | |
| Operating income | −100−1099%−21.6% | −10—−8.5% | −17−295%−15.3% | −57—−56.2% | −14*−262%−11.8% | −3.3—−2.8% | 9.0—8.7% | −4.6—−5.2% | 8.8*—9.2% | −7.8—−10.1% | −11—−15.0% | −14—−21.9% | −26*—−44.7% | |
| Net interest income | — | — | — | — | — | — | — | — | — | — | — | −0.6—−1.0% | −1.0*—−1.7% | |
| Other non-operating income (expense) | −12—−2.5% | −1.9—−1.5% | −0.8−150%−0.7% | −4.9—−4.8% | −4.0*—−3.3% | −4.1—−3.5% | 1.6—1.6% | −1.5—−1.8% | −3.4*—−3.5% | −0.6—−0.8% | −19—−26.6% | −6.7—−10.7% | −0.5*—−0.9% | |
| Income before tax | −111−4536%−24.1% | −12—−10.0% | −18−273%−16.0% | −62—−61.0% | −18*−437%−15.1% | −7.4—−6.3% | 11—10.3% | −6.1—−7.0% | 5.4*—5.7% | −8.4—−10.9% | −29—−41.6% | −20—−32.6% | −26*—−45.6% | |
| Income tax | −0.2−138%−0.0% | 0.0−89.5%0.0% | −0.5—−0.5% | 0.9+101%0.9% | −0.6*—−0.5% | 0.2—0.2% | −0.2—−0.2% | 0.4—0.5% | −0.0*—−0.0% | −0.0—−0.1% | −0.2—−0.3% | −0.1—−0.1% | −0.4*—−0.7% | |
| Net income attributable to shareholders | −111−5431%−24.1% | −12—−10.0% | −18−264%−15.5% | −63—−61.9% | −18*−425%−14.6% | −7.6—−6.5% | 11—10.5% | −6.5—−7.5% | 5.4*—5.7% | −8.3—−10.8% | −29—−41.4% | −20—−32.4% | −26*—−44.9% | |
| Earnings per share, basic | — | -0.41—— | -0.60−258%— | -2.16—— | — | -0.27—— | 0.38—— | -0.23—— | — | -0.31—— | -1.10—— | -0.78—— | — | |
| Earnings per share, diluted | — | -0.41—— | -0.60−267%— | -2.16—— | — | -0.27—— | 0.36—— | -0.23—— | — | -0.31—— | -1.10—— | -0.78—— | — | |
| Shares, weighted average (basic) | 30+3.8%— | 30+3.8%— | 30+4.0%— | 29+4.2%— | — | 29+6.3%— | 29+7.4%— | 28+8.0%— | — | 27—— | 27—— | 26—— | — | |
| Shares, weighted average (diluted) | 30+3.8%— | 30+3.8%— | 30−0.1%— | 29+4.2%— | — | 29+6.3%— | 30+11.8%— | 28+8.0%— | — | 27—— | 27—— | 26—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 96—18.3% | 96+0.2%18.3% | 60−18.6%12.5% | 94−5.8%18.6% | 105+23.2%20.0% | 96+65.8%19.4% | 74+32.2%16.0% | 100+19.2%22.3% | 85−14.5%20.3% | 58—14.2% | 56—14.4% | 84—21.2% | 100—23.8% | |
| Short-term investments | 74—14.1% | 74+25.2%14.1% | 72+19.5%15.0% | 77+29.1%15.2% | 66+18.4%12.7% | 59+0.9%12.0% | 60+19.0%13.0% | 59+103%13.3% | 56+83.7%13.3% | 59—14.3% | 51—13.1% | 29—7.4% | 30—7.3% | |
| Receivables | 92—17.5% | 92+51.2%17.5% | 84+74.1%17.4% | 77+67.3%15.2% | 74+97.6%14.2% | 61—12.3% | 48—10.4% | 46—10.3% | 38r37—9.0% | — | — | — | — | |
| Inventory | 22—4.1% | 22+105%4.1% | 18+49.3%3.7% | 12−3.3%2.4% | 14+31.0%2.7% | 11−1.9%2.1% | 12+15.6%2.6% | 13+9.0%2.8% | 11+21.3%2.5% | 11—2.6% | 10—2.7% | 12—2.9% | 8.8—2.1% | |
| Other current assets | 1.6—0.3% | 1.6−11.4%0.3% | 1.0−46.7%0.2% | 1.0−87.4%0.2% | 1.5+40.0%0.3% | 1.9−85.3%0.4% | 1.9−82.9%0.4% | 8.0−19.7%1.8% | 1.1r1.1−44.9%0.3% | 13—3.1% | 11—2.9% | 10.0—2.5% | 2.0r11—0.5% | |
| Current assets | 297—56.4% | 297+25.0%56.4% | 246+20.3%51.2% | 271+19.8%53.5% | 268+35.5%51.2% | 238+27.7%48.1% | 205+26.3%44.2% | 226+38.2%50.6% | 198+8.6%47.2% | 186—45.5% | 162—41.7% | 163—41.4% | 182—43.5% | |
| Property, plant and equipment | 54—10.2% | 54+26.2%10.2% | 54+35.4%11.3% | 50+37.8%9.9% | 46+38.9%8.7% | 42+34.9%8.6% | 40+28.0%8.6% | 36+16.2%8.1% | 33+1.3%7.8% | 31—7.7% | 31—8.1% | 31—7.9% | 32—7.8% | |
| Right-of-use (leased) assets | 32—6.2% | 32+33.9%6.2% | 34+34.3%7.0% | 35+39.3%6.8% | 23−8.6%4.5% | 24−3.0%4.9% | 25−2.5%5.4% | 25−5.4%5.6% | 26−4.8%6.1% | 25—6.1% | 26—6.6% | 26—6.7% | 27—6.4% | |
| Goodwill | 1.6—0.3% | 1.6−87.2%0.3% | 1.6−87.3%0.3% | 1.6—0.3% | 14—2.6% | 13—2.6% | 13—2.8% | — | 0—0.0% | — | — | — | — | |
| Other intangible assets | 138—26.2% | 138−20.2%26.2% | 141−20.0%29.4% | 145−6.5%28.6% | 168+6.2%32.2% | 173+6.5%34.9% | 177+6.7%38.1% | 155−8.3%34.7% | 159−8.1%37.8% | 162—39.7% | 166—42.6% | 169—42.9% | 173—41.2% | |
| Total assets | 526—100% | 526+6.6%100% | 481+3.8%100% | 506+13.4%100% | 524+24.9%100% | 494+20.8%100% | 464+19.2%100% | 446+13.2%100% | 419+0.1%100% | 409—100% | 389—100% | 395—100% | 419—100% | |
| Accounts payable | 3.3—0.6% | 3.3+26.2%0.6% | 5.1+46.1%1.1% | 11−29.6%2.2% | 2.5−69.1%0.5% | 2.6−70.8%0.5% | 3.5−56.7%0.8% | 16+67.3%3.6% | 8.0−22.3%1.9% | 9.0—2.2% | 8.1—2.1% | 9.5—2.4% | 10—2.4% | |
| Debt due within a year | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 4.5+275%0.9% | 1.2+2.0%0.2% | 1.2+11.2%0.3% | 1.2+52.5%0.3% | 1.2+144%0.3% | 1.2—0.3% | 1.1—0.3% | 0.8—0.2% | 0.5—0.1% | |
| Current liabilities | 71—13.6% | 71−18.5%13.6% | 75+4.5%15.5% | 88+26.0%17.3% | 109+98.7%20.8% | 88+13.3%17.7% | 71+4.6%15.4% | 70+37.1%15.6% | 55−6.8%13.1% | 77—18.9% | 68—17.5% | 51—12.9% | 59—14.0% | |
| Long-term debt | 146—27.8% | 146+184%27.8% | 97+87.4%20.1% | 97+86.8%19.1% | 48−7.2%9.2% | 52−0.9%10.4% | 52−0.9%11.1% | 52−1.0%11.6% | 52−1.5%12.4% | 52—12.7% | 52—13.4% | 52—13.3% | 53—12.6% | |
| Lease liabilities (non-current) | — | — | — | — | 39−9.2%7.4% | — | — | — | 43−3.9%10.2% | — | — | — | 44—10.6% | |
| Total liabilities | 282—53.5% | 282+39.7%53.5% | 237+27.1%49.3% | 252+33.4%49.8% | 216+23.8%41.2% | 202−1.3%40.8% | 187−4.3%40.3% | 189+0.9%42.3% | 174−8.7%41.5% | 204—50.0% | 195—50.1% | 187—47.5% | 191—45.5% | |
| Retained earnings | −1,467—−279% | −1,467—−279% | −1,455—−302% | −1,437—−284% | −1,373—−262% | −1,356—−275% | −1,348—−291% | −1,359—−304% | −1,352—−322% | −1,358—−332% | −1,350—−347% | −1,320—−335% | −1,300—−310% | |
| Shareholders' equity | 245—46.5% | 245−16.3%46.5% | 244−11.9%50.7% | 254−1.3%50.2% | 308+25.7%58.8% | 292+42.9%59.2% | 277+42.8%59.7% | 257+24.2%57.7% | 245+7.6%58.5% | 205—50.0% | 194—49.9% | 207—52.5% | 228—54.5% | |
| Total liabilities and equity | 526—100% | 526+6.6%100% | 481+3.8%100% | 506+13.4%100% | 524+24.9%100% | 494+20.8%100% | 464+19.2%100% | 446+13.2%100% | 419+0.1%100% | 409—100% | 389—100% | 395—100% | 419—100% | |
| Shares outstanding | 30—— | 30+3.7%— | 30+3.8%— | 30+4.0%— | 29+4.4%— | 29+5.3%— | 29+6.6%— | 29+9.2%— | 28+7.8%— | 27—— | 27—— | 26—— | 26—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 12+33.3%2.6% | 3.3+37.5%2.7% | 3.1+34.8%2.7% | 2.7+22.7%2.6% | 2.8r2.8*+38.3%2.3% | 2.4r2.4−0.9%2.1% | 2.3r2.3+34.3%2.2% | 2.2r2.2+26.3%2.5% | 2.0*−21.5%2.1% | 2.4—3.2% | 1.7—2.4% | 1.7—2.8% | 2.6*—4.5% | |
| Share-based compensation | 33+32.3%7.2% | 8.3−22.0%6.7% | 6.3−18.8%5.5% | 9.0+126%8.8% | 9.8*+244%8.1% | 11+191%9.1% | 7.8+151%7.6% | 4.0—4.6% | 2.8*—3.0% | 3.6—4.7% | 3.1—4.4% | −0.5—−0.7% | — | |
| Cash from operating activities | −75−326%−16.3% | −11*−167%−8.6% | −29*−378%−25.3% | −32−418%−31.7% | −3.1*—−2.6% | 16*—13.5% | 10*—10.1% | 10—11.7% | −3.2*—−3.3% | −4.4*—−5.7% | −4.5*—−6.4% | −16—−26.3% | −30*—−52.0% | |
| Capital expenditure | — | — | −10*—−8.8% | −6.5—−6.3% | −4.3*—−3.6% | −6.2*—−5.3% | −2.4*—−2.3% | −6.1—−7.0% | −3.1*—−3.2% | −0.6*—−0.8% | −1.4*—−1.9% | −0.4—−0.7% | −2.4*—−4.1% | |
| Acquisitions, net of cash acquired | — | 0*—0.0% | — | — | — | 0*—0.0% | — | — | 0*—0.0% | 0*—0.0% | — | — | 0*—0.0% | |
| Cash from investing activities | −41—−9.0% | −7.4*—−6.0% | −5.6*—−4.9% | −17—−16.9% | −11*—−9.2% | −4.7*—−4.0% | −36*—−35.4% | −9.4−1216%−10.8% | −0.5*—−0.5% | −7.8*—−10.1% | −23*—−32.2% | 0.8—1.4% | −4.9*—−8.5% | |
| Debt issued | — | 49*—40.1% | — | — | 0*—0.0% | 0*—0.0% | — | — | — | — | — | — | — | |
| Shares issued | — | — | 0*—0.0% | 0.5—0.5% | — | — | 0*—0.0% | 0—0.0% | — | — | — | — | — | |
| Cash from financing activities | 117+109%25.3% | 54*+400%43.7% | 1.0*+190%0.9% | 39+181%37.7% | 23*−25.2%19.2% | 11*−22.9%9.2% | 0.3*—0.3% | 14—15.7% | 31*−34.1%32.4% | 14*—18.2% | −0.4*—−0.6% | −0.4—−0.7% | 47*—82.0% | |
| Change in cash | 0.2−99.5%0.0% | 36*+64.0%29.1% | −34*—−29.4% | −11−176%−10.8% | 9.0*−66.9%7.5% | 22*+1102%18.7% | −26*—−24.9% | 14—16.6% | 27*+121%28.6% | 1.8*—2.4% | −28*—−39.1% | −16—−25.6% | 12*—21.6% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What GeneDx Holdings Corp. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Diagnostic Test$417 M97%+38%
- Patients with third-party insurance$345 M81%+47%
- Institutional customers$70 M16%+7.6%
- Other revenue$11 M2.5%+230%
- Self-pay patients$1 M0.3%-42%
Business segments
- GeneDx$423 M99%+40%
- Other$4 M1.0%+41%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where GeneDx Holdings Corp. operates: 1 country#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
Only the headquarters country is on file for GeneDx Holdings Corp.: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at GeneDx Holdings Corp.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Katherine Stueland | $13.5 M | $43.4 M | $4.1 M | $1494 (peers $139) |
| 2024Katherine Stueland | $4.4 M | $51.5 M | $896 K | $883 (peers $104) |
| 2023Katherine Stueland | $3.5 M | $546 K | $1.2 M | $32 (peers $105) |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at GeneDx Holdings Corp.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 3 · Material agreement 3 · Agreement ended 1 · New debt 1 · Unregistered share sale 1 · Shareholder vote 3 · Results announced 15
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementAgreement endedNew debt | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
2 acquisitions, $49 M paid where reported
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Fabric Genomics, Inc | 2025 | — | $37 M | — | Annual report |
| GeneDx | 2023 | — | $12 M | — | Annual report |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by GeneDx Holdings Corp.#
$240 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues and medicare/medicaid.
- Health Issues3 reports
- Medicare/Medicaid3 reports
Lobbying firms hired in 2025
Red+Blue Strategies( formerly known as Nathanson+Hauck) $160 K · Red+Blue Strategies $80 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $270 K | — | 4 |
| 2025 | $240 K | — | 3 |
| 2022 | $53 K | — | 2 |
| 2021 | $0 | — | 1 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “GeneDx, LLC”, “GeneDx, Inc.” and “GeneDx”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at GeneDx Holdings Corp.#
4 labor condition applications certified in fiscal 2026 for 4 positions, at a median wage of $163 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Backend Software EngineerSoftware Developers | 2 | $125 K |
| Director, CX Engineering-Order ManagementComputer and Information Systems Managers | 1 | $203 K |
| Senior Director, Strategic ForecastingBusiness Intelligence Analysts | 1 | $200 K |
Where: Binghamton, NY 2 · Lisle, IL 1 · New York, NY 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 4 | 4 | $163 K | 4 |
| FY2024 | 1 | 1 | $200 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as GeneDx, LLC
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | · | · | · | · | · | · | · | · | · | · | 500 | · | 500 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 500 people (32.5% of workforce) | Restructuring planSEC 8-K | “As a result of this announcement, the Company expects to eliminate approximately 500 positions, representing approximately 32.5% of its workforce, and to cease operations at its St…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
Discuss GeneDx Holdings Corp.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 9 November 2026automatic update · Nov 9, 2026
GeneDx Holdings Corp. announced results on 9 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $123 million (up 5% from a year earlier) and a net loss of $12 million.
- Mutual funds: 180 funds hold $458 millionautomatic update · Jul 31, 2026
180 mutual funds in 2 countries hold shares of GeneDx Holdings Corp. worth $458 million, about 23.3% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 117 funds added shares and 107 sold; on balance they sold $173 million. Share splits are not counted as trading.
Questions, comparisons and similar companies#
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at GeneDx Holdings Corp.? Verify and update this profile — free
Show GeneDx Holdings Corp.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.